Rabbit anti-T cell globulin in allogeneic hematopoietic cell transplantation.

[1]  J. Szer,et al.  Older recipient age is paradoxically associated with a lower incidence of chronic GVHD in Thymoglobulin recipients: a retrospective study exploring risk factors for GVHD in allogeneic transplantation with Thymoglobulin GVHD prophylaxis , 2015, Bone Marrow Transplantation.

[2]  M. Labopin,et al.  Impact of rabbit ATG-containing myeloablative conditioning regimens on the outcome of patients undergoing unrelated single-unit cord blood transplantation for hematological malignancies , 2015, Bone Marrow Transplantation.

[3]  C. Knibbe,et al.  Population Pharmacokinetic Modeling of Thymoglobulin® in Children Receiving Allogeneic-Hematopoietic Cell Transplantation: Towards Improved Survival Through Individualized Dosing , 2015, Clinical Pharmacokinetics.

[4]  T. Panzarella,et al.  Thymoglobulin Decreases the Need for Immunosuppression at 12 Months after Myeloablative and Nonmyeloablative Unrelated Donor Transplantation: CBMTG 0801, a Randomized, Controlled Trial , 2014 .

[5]  N. Kröger,et al.  Prevention of Chronic GvHD after HLA-Identical Sibling Peripheral Hematopietic Stem Cell Transplantation with or without Anti-Lymphocyte Globulin (ATG). Results from a Prospective, Multicenter Randomized Phase III Trial (ATGfamilystudy) , 2014 .

[6]  J. Bourhis,et al.  Higher Doses of Antithymocyte Globulin (ATG) Increase the Risk of Relapse in Acute Myeloid Leukemia (AML) Patients Undergoing Matched Related Donor Allogeneic Transplantation in First Complete Remission (CR1): An Analysis from the Acute Leukemia Working Party of EBMT , 2014 .

[7]  J. Wagner,et al.  The effect of equine antithymocyte globulin on the outcomes of reduced intensity conditioning for AML , 2014, Bone Marrow Transplantation.

[8]  C. Griffiths,et al.  High serum level of antithymocyte globulin immediately before graft infusion is associated with a low likelihood of chronic, but not acute, graft-versus-host disease. , 2014, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[9]  M. Robin,et al.  Antithymocyte globulin before allogeneic stem cell transplantation for progressive myelodysplastic syndrome: a study from the French Society of Bone Marrow Transplantation and Cellular Therapy. , 2014, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[10]  E. V. van Maarseveen,et al.  Fludarabine and exposure-targeted busulfan compares favorably with busulfan/cyclophosphamide-based regimens in pediatric hematopoietic cell transplantation: maintaining efficacy with less toxicity. , 2014, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[11]  L. Xu,et al.  Influence of two different doses of antithymocyte globulin in patients with standard-risk disease following haploidentical transplantation: a randomized trial , 2014, Bone Marrow Transplantation.

[12]  C. Knibbe,et al.  Exposure of Thymoglobulin Is Associated with Overall Survival in Children Receiving Allogeneic-Hematopoietic Cell Transplantation (HCT): Towards Individualized Dosing to Improve Survival , 2014 .

[13]  C. Knibbe,et al.  Population Pharmacokinetic Modeling of Thymoglobulin in Children Receiving Allogeneic-Hematopoietic Cell Transplantation (HCT): Towards Individualized Dosing to Improve Survival , 2014 .

[14]  W. Wiktor-Jedrzejczak,et al.  Prophylaxis and treatment of GVHD: EBMT–ELN working group recommendations for a standardized practice , 2014, Bone Marrow Transplantation.

[15]  N. Kröger,et al.  Effective prevention of GVHD using in vivo T-cell depletion with anti-lymphocyte globulin in HLA-identical or -mismatched sibling peripheral blood stem cell transplantation , 2014, Bone Marrow Transplantation.

[16]  P. Veys,et al.  Impact of thymoglobulin prior to pediatric unrelated umbilical cord blood transplantation on immune reconstitution and clinical outcome. , 2014, Blood.

[17]  T. Braun,et al.  ST2 as a marker for risk of therapy-resistant graft-versus-host disease and death. , 2013, The New England journal of medicine.

[18]  P. Ljungman,et al.  A high antithymocyte globulin dose increases the risk of relapse after reduced intensity conditioning HSCT with unrelated donors , 2013, Clinical transplantation.

[19]  A. Lyon,et al.  IL15 levels on day 7 after hematopoietic cell transplantation predict chronic GVHD , 2013, Bone Marrow Transplantation.

[20]  J. Storek,et al.  Prognosis of grade 3–4 acute GVHD continues to be dismal , 2013, Bone Marrow Transplantation.

[21]  R. Bouabdallah,et al.  Two days of antithymocyte globulin are associated with a reduced incidence of acute and chronic graft‐versus‐host disease in reduced‐intensity conditioning transplantation for hematologic diseases , 2013, Cancer.

[22]  J. Szer,et al.  High Donor and Recipient Age Are Not Risk Factors for Chronic Graft-Versus-Host Disease in the Setting of Anti-Thymocyte Globulin-Conditioned Hematopoietic Stem Cell Transplantation , 2013 .

[23]  A. Bacigalupo,et al.  Front-line immunosuppressive treatment of acquired aplastic anemia , 2013, Bone Marrow Transplantation.

[24]  E. Thiel,et al.  Rabbit antithymocyte globulin (Thymoglobulin®) impairs the thymic output of both conventional and regulatory CD4+ T cells after allogeneic hematopoietic stem cell transplantation in adult patients , 2013, Haematologica.

[25]  J. Storek,et al.  Anti-thymocyte globulins capable of binding to T and B cells reduce graft-vs-host disease without increasing relapse , 2013, Bone Marrow Transplantation.

[26]  F. Baron,et al.  Impact of graft-versus-host disease after reduced-intensity conditioning allogeneic stem cell transplantation for acute myeloid leukemia: a report from the Acute Leukemia Working Party of the European group for blood and marrow transplantation , 2012, Leukemia.

[27]  D. Maloney,et al.  Immune reconstitution after anti-thymocyte globulin-conditioned hematopoietic cell transplantation. , 2012, Cytotherapy.

[28]  Jun Zhu,et al.  Polyclonal rabbit antithymocyte globulin induces apoptosis and has cytotoxic effects on human leukemic cells. , 2012, Clinical lymphoma, myeloma & leukemia.

[29]  H. Heslop,et al.  T-cell therapy in the treatment of post-transplant lymphoproliferative disease , 2012, Nature Reviews Clinical Oncology.

[30]  M. Remberger,et al.  Effects of different serum-levels of ATG after unrelated donor umbilical cord blood transplantation. , 2012, Transplant immunology.

[31]  M. Baccarani,et al.  Intensification of GVHD prophylaxis with low-dose ATG-F before allogeneic PBSC transplantation from HLA-identical siblings in adult patients with hematological malignancies: results from a retrospective analysis , 2012, Bone Marrow Transplantation.

[32]  Jian Cheng,et al.  Quality of life of patients after allogeneic hematopoietic stem cell transplantation with antihuman thymocyte globulin. , 2012, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[33]  Yong Wang,et al.  A retrospective comparison of the efficacy and safety in kidney transplant recipients with basiliximab and anti-thymocyte globulin. , 2012, Chinese medical journal.

[34]  P. Veys,et al.  Omission of in vivo T‐cell depletion promotes rapid expansion of naïve CD4+ cord blood lymphocytes and restores adaptive immunity within 2 months after unrelated cord blood transplant , 2012, British journal of haematology.

[35]  R. Egeler,et al.  IgG antibodies to ATG early after pediatric hematopoietic SCT increase the risk of acute GVHD , 2012, Bone Marrow Transplantation.

[36]  O. Majdic,et al.  Assessment of Batch to Batch Variation in Polyclonal Antithymocyte Globulin Preparations , 2012, Transplantation.

[37]  G. Driessen,et al.  Paediatric Reference Values for the Peripheral T cell Compartment , 2011, Scandinavian journal of immunology.

[38]  S. Paczesny,et al.  Clinical applications for biomarkers of acute and chronic graft-versus-host disease. , 2012, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[39]  A. Nagler,et al.  Anti-T Lymphocyte Globulin (ATG) Induces Generation of Regulatory T Cells, at Least Part of Them Express Activated CD44 , 2012, Journal of Clinical Immunology.

[40]  N. Young,et al.  Horse versus rabbit antithymocyte globulin in acquired aplastic anemia. , 2011, The New England journal of medicine.

[41]  D. Porter,et al.  Impact of immune modulation with anti-T-cell antibodies on the outcome of reduced-intensity allogeneic hematopoietic stem cell transplantation for hematologic malignancies. , 2011, Blood.

[42]  H. Einsele,et al.  Chronic graft-versus-host disease: long-term results from a randomized trial on graft-versus-host disease prophylaxis with or without anti-T-cell globulin ATG-Fresenius. , 2011, Blood.

[43]  M. Boeckh,et al.  Evaluating the impact of antithymocyte globulin on lung function at 1 year after allogeneic stem cell transplantation. , 2011, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[44]  K. Fonseca,et al.  Donor serostatus has an impact on cytomegalovirus-specific immunity, cytomegaloviral disease incidence, and survival in seropositive hematopoietic cell transplant recipients. , 2011, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[45]  R. Storb,et al.  Comparative analysis of risk factors for acute graft-versus-host disease and for chronic graft-versus-host disease according to National Institutes of Health consensus criteria. , 2011, Blood.

[46]  O. Majdic,et al.  Interaction of Antithymocyte Globulins with Dendritic Cell Antigens , 2011, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[47]  N. Mahmud,et al.  Human CD4(+)CD25(+) Cells in Combination with CD34(+) Cells and Thymoglobulin to Prevent Anti-hematopoietic Stem Cell T Cell Alloreactivity. , 2011, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[48]  J. Bourhis,et al.  Antithymocyte globulins and chronic graft-vs-host disease after myeloablative allogeneic stem cell transplantation from HLA-matched unrelated donors: a report from the Sociéte Française de Greffe de Moelle et de Thérapie Cellulaire , 2010, Leukemia.

[49]  J. Storek,et al.  High rabbit-antihuman thymocyte globulin levels are associated with low likelihood of graft-vs-host disease and high likelihood of posttransplant lymphoproliferative disorder. , 2010, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[50]  M. Boeckh,et al.  Cytomegalovirus in hematopoietic stem cell transplant recipients. , 2010, Infectious disease clinics of North America.

[51]  P. Bartolomeo,et al.  Pre-emptive treatment of acute GVHD: a randomized multicenter trial of rabbit anti-thymocyte globulin, given on day+7 after alternative donor transplants , 2010, Bone Marrow Transplantation.

[52]  B. Sandmaier,et al.  Defining the intensity of conditioning regimens: working definitions. , 2009, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[53]  J. Byrd,et al.  Improved nonrelapse mortality and infection rate with lower dose of antithymocyte globulin in patients undergoing reduced-intensity conditioning allogeneic transplantation for hematologic malignancies. , 2009, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[54]  H. Einsele,et al.  Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial. , 2009, The Lancet. Oncology.

[55]  M. Remberger,et al.  Low serum levels of total rabbit-IgG is associated with acute graft-versus-host disease after unrelated donor hematopoietic stem cell transplantation: results from a prospective study. , 2009, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[56]  M. Ruzek,et al.  In Vivo Characterization of Rabbit Anti-Mouse Thymocyte Globulin: A Surrogate for Rabbit Anti-Human Thymocyte Globulin , 2009, Transplantation.

[57]  John M. Williams,et al.  Polyclonal Rabbit Antithymocyte Globulin Exhibits Consistent Immunosuppressive Capabilities Beyond Cell Depletion , 2009, Transplantation.

[58]  N. Kröger,et al.  Comparison of the cytotoxicity of 4 preparations of anti-T-cell globulins in various hematological malignancies. , 2009, Anticancer research.

[59]  C. Ziegler,et al.  Rabbit anti T-lymphocyte globulin induces apoptosis in peripheral blood mononuclear cell compartments and leukemia cells, while hematopoetic stem cells are apoptosis resistant. , 2009, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[60]  J. Panetta,et al.  Total and active rabbit antithymocyte globulin (rATG;Thymoglobulin) pharmacokinetics in pediatric patients undergoing unrelated donor bone marrow transplantation. , 2009, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[61]  C. Bokemeyer,et al.  Complement-dependent and complement-independent cytotoxicity of polyclonal antithymocyte globulins in chronic lymphocytic leukemia. , 2008, Leukemia research.

[62]  P. Munson,et al.  Rabbit ATG but not horse ATG promotes expansion of functional CD4+CD25highFOXP3+ regulatory T cells in vitro. , 2007, Blood.

[63]  J. Fricker.  American Society of Hematology annual meeting. , 2008, The Lancet. Oncology.

[64]  W. Hörl,et al.  Antithymocyte globulin impairs T-cell/antigen-presenting cell interaction: disruption of immunological synapse and conjugate formation. , 2007, Transplantation.

[65]  M. Mohty,et al.  Mechanisms of action of antithymocyte globulin: T-cell depletion and beyond , 2007, Leukemia.

[66]  J. Klein,et al.  Bone marrow transplantation for severe aplastic anemia: a randomized controlled study of conditioning regimens. , 2007, Blood.

[67]  A. Turner,et al.  Adult recipients of matched related donor blood cell transplants given myeloablative regimens including pretransplant antithymocyte globulin have lower mortality related to graft-versus-host disease: a matched pair analysis. , 2007, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[68]  G. Opelz,et al.  Antithymocyte Globulins Suppress Dendritic Cell Function by Multiple Mechanisms , 2007, Transplantation.

[69]  J. Wagner,et al.  Antigen-specific T-lymphocyte function after cord blood transplantation. , 2006, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[70]  D. Rigal,et al.  Rabbit Antithymocyte Globulin Inhibits Monocyte-Derived Dendritic Cells Maturation In Vitro and Polarizes Monocyte-Derived Dendritic Cells Towards Tolerogenic Dendritic Cells Expressing Indoleamine 2,3-dioxygenase , 2006, Transplantation.

[71]  A. Bacigalupo,et al.  Treatment of acute graft-versus-host disease with prednisolone: significant survival advantage for day +5 responders and no advantage for nonresponders receiving anti-thymocyte globulin. , 2006, Blood.

[72]  P. Bruzzi,et al.  Thymoglobulin prevents chronic graft-versus-host disease, chronic lung dysfunction, and late transplant-related mortality: long-term follow-up of a randomized trial in patients undergoing unrelated donor transplantation. , 2006, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[73]  M. Heemskerk,et al.  Pretransplantation CMV-specific T cells protect recipients of T-cell-depleted grafts against CMV-related complications. , 2006, Blood.

[74]  T. Lion,et al.  Antithymocyte Globulin Pharmacokinetics in Pediatric Patients After Hematopoietic Stem Cell Transplantation , 2005, Journal of pediatric hematology/oncology.

[75]  J. Wagner,et al.  Effect of graft-versus-host disease prophylaxis on 3-year disease-free survival in recipients of unrelated donor bone marrow (T-cell Depletion Trial): a multi-centre, randomised phase II–III trial , 2005, The Lancet.

[76]  W. Kraft,et al.  Heterogeneous clearance of antithymocyte globulin after CD34+-selected allogeneic hematopoietic progenitor cell transplantation. , 2005, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[77]  A. Yoshimi,et al.  Leukemic cell death induced by antithymocyte globulin. , 2005, Leukemia research.

[78]  M. Labopin,et al.  Antithymocyte globulin for the prevention of graft-versus-host disease after unrelated hematopoietic stem cell transplantation for acute myeloid leukemia: results from the multicenter German cooperative study group , 2005, Bone Marrow Transplantation.

[79]  N. Kröger,et al.  Antithymocyte globulin induces ex vivo and in vivo depletion of myeloid and plasmacytoid dendritic cells. , 2005, Transplantation.

[80]  A. Bacigalupo.  Antilymphocyte/thymocyte globulin for graft versus host disease prophylaxis: efficacy and side effects , 2005, Bone Marrow Transplantation.

[81]  M. Remberger,et al.  Dose Study of Thymoglobulin During Conditioning for Unrelated Donor Allogeneic Stem-Cell Transplantation , 2004, Transplantation.

[82]  I. Joosten,et al.  Addition of ATG to the conditioning regimen is a major determinant for outcome after transplantation with partially lymphocyte-depleted grafts from voluntary unrelated donors , 2004, Bone Marrow Transplantation.

[83]  R. Krance,et al.  Prompt versus preemptive intervention for EBV lymphoproliferative disease. , 2004, Blood.

[84]  P. Ljungman,et al.  Which donor should be chosen for hematopoietic stem cell transplantation among unrelated HLA-A, -B, and -DRB1 genomically identical volunteers? , 2004, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[85]  A. Dejean,et al.  Alloreactive CD4 T lymphocytes responsible for acute and chronic graft‐versus‐host disease are contained within the CD45RChigh but not the CD45RClow subset , 2004, European journal of immunology.

[86]  Y. Lebranchu,et al.  Induction therapy by anti‐thymocyte globulin (rabbit) in renal transplantation: a 1‐yr follow‐up of safety and efficacy , 2003, Clinical transplantation.

[87]  N. Kröger,et al.  ATG as part of the conditioning regimen reduces transplant-related mortality (TRM) and improves overall survival after unrelated stem cell transplantation in patients with chronic myelogenous leukemia (CML) , 2003, Bone Marrow Transplantation.

[88]  G. Ledderose,et al.  Dose-dependent effects of in vivo antithymocyte globulin during conditioning for allogeneic bone marrow transplantation from unrelated donors in patients with chronic phase CML , 2003, Bone Marrow Transplantation.

[89]  M. Sormani,et al.  A revised day +7 predictive score for transplant-related mortality: serum cholinesterase, total protein, blood urea nitrogen, γ glutamyl transferase, donor type and cell dose , 2003, Bone Marrow Transplantation.

[90]  S. Lonial,et al.  Pharmacokinetics and pharmacodynamics of anti-thymocyte globulin in recipients of partially HLA-matched blood hematopoietic progenitor cell transplantation. , 2003, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[91]  F. Frommlet,et al.  Pre-emptive treatment of CMV DNAemia in paediatric stem cell transplantation: the impact of recipient and donor CMV serostatus on the incidence of CMV disease and CMV-related mortality , 2003, Bone Marrow Transplantation.

[92]  N. Kröger,et al.  Influence of anti-thymocyte globulin as part of the conditioning regimen on immune reconstitution following matched related bone marrow transplantation. , 2003, Journal of hematotherapy & stem cell research.

[93]  J. Squifflet,et al.  A three-arm study comparing immediate tacrolimus therapy with antithymocyte globulin induction therapy followed by tacrolimus or cyclosporine A in adult renal transplant recipients1 , 2003, Transplantation.

[94]  P. Allavena,et al.  Effects of anti-lymphocytes and anti-thymocytes globulin on human dendritic cells. , 2003, International immunopharmacology.

[95]  P. Bruzzi,et al.  Antithymocyte globulin for graft-versus-host disease prophylaxis in transplants from unrelated donors: 2 randomized studies from Gruppo Italiano Trapianti Midollo Osseo (GITMO). , 2001, Blood.

[96]  J. Squifflet,et al.  INDUCTION VERSUS NONINDUCTION IN RENAL TRANSPLANT RECIPIENTS WITH TACROLIMUS-BASED IMMUNOSUPPRESSION1 , 2001, Transplantation.

[97]  A. Zander,et al.  Patient cytomegalovirus seropositivity with or without reactivation is the most important prognostic factor for survival and treatment‐related mortality in stem cell transplantation from unrelated donors using pretransplant in vivo T‐cell depletion with anti‐thymocyte globulin , 2001, British journal of haematology.

[98]  G. Dini,et al.  Graft versus host disease prophylaxis with low-dose cyclosporine-A reduces the risk of relapse in children with acute leukemia given HLA-identical sibling bone marrow transplantation: results of a randomized trial. , 2000, Blood.

[99]  F. Berthoux,et al.  Advantage of antithymocyte globulin induction in sensitized kidney recipients: a randomized prospective study comparing induction with and without antithymocyte globulin. , 1998, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[100]  J. Forsythe,et al.  The paradox of ATG monitoring in renal transplantation. , 1994, Transplantation proceedings.

[101]  A. Rimm,et al.  T-cell depletion of HLA-identical transplants in leukemia. , 1991, Blood.

[102]  F. Frassoni,et al.  Increased risk of leukemia relapse with high-dose cyclosporine A after allogeneic marrow transplantation for acute leukemia. , 1991, Blood.

[103]  H. Deeg,et al.  Methotrexate and cyclosporine versus cyclosporine alone for prophylaxis of graft-versus-host disease in patients given HLA-identical marrow grafts for leukemia: long-term follow-up of a controlled trial. , 1989, Blood.

[104]  R. Storb,et al.  Failure of early administration of antithymocyte globulin to lessen graft-versus-host disease in human allogeneic marrow transplant recipients. , 1981, Transplantation.